SCM
RAPP

Sterling Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Sterling Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.88K Sell
141
-834
-86% -$30.7K ﹤0.01% 2526
2026
Q1 		$30.5K Sell
975
-665
-41% -$18.7K ﹤0.01% 1835
2025
Q4 		$49.8K Buy
1,640
+429
+35% +$11.9K ﹤0.01% 1804
2025
Q3 		$36K Buy
1,211
+737
+155% +$13.1K ﹤0.01% 1881
2025
Q2 		$5.39K Buy
474
+329
+227% +$3.49K ﹤0.01% 2464
2025
Q1 		$1.45K Buy
145
+2
+1% +$26 ﹤0.01% 2691
2024
Q4 		$2.54K Buy
143
+124
+653% +$2.75K ﹤0.01% 2713
2024
Q3 		$389 Buy
+19
New +$408 ﹤0.01% 2970

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Sterling Capital Management's RAPP Position: Q2 2026 in Review

Sterling Capital Management reduced its Rapport Therapeutics (RAPP) stake by 86% in Q2 2026, selling an estimated $30.7K and leaving 141 shares worth $5.88K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

Sterling Capital Management first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. The position peaked at $49.8K in Q4 2025. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Sterling Capital Management held 141 shares of Rapport Therapeutics worth $5.88K as of Q2 2026.
  • Sterling Capital Management sold 834 Rapport Therapeutics shares in Q2 2026, an estimated $30.7K.
  • Rapport Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2526 holding.
  • Sterling Capital Management first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Rapport Therapeutics position peaked at $49.8K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.